Polaroid Therapeutics Reports Progress in Wound Care

Schlieren, ZH – Polaroid Therapeutics achieves preclinical success in developing antimicrobial polymer technology for acute and chronic wounds. It reduces bacterial load without triggering antimicrobial resistance.

According to a press release, the medical technology start-up Polaroid Therapeutics in Schlieren has achieved success in the development of its wound care therapy. Polaroid Therapeutics is developing antimicrobial polymer technology. The polymers in the newly developed wound dressings destroy bacterial cells. They have an immediate and long-lasting effect without causing antimicrobial resistance (AMR).

Today, misuse and overuse of antimicrobial agents are the main causes of AMR. When too much antibiotics and antimicrobial agents are used, bacteria, viruses, fungi, and parasites can adapt to them, causing these treatments to lose effectiveness over time, the release states.

According to the World Health Organization, antibiotic resistance is one of the greatest global threats to public health and development. It is estimated that bacterial AMR was directly responsible for 1.27 million deaths worldwide in 2019 and contributed to 4.95 million deaths.

"Medical needs remain unmet worldwide, meaning patients are at risk of serious long-term complications," said Ran Frenkel, CEO and co-founder of Polaroid Therapeutics.

The global market for advanced wound dressings (AWD) was estimated at $4.5 billion in 2022 and is expected to grow at an average annual rate of 4.5% from 2023 to 2030, with antimicrobial products accounting for a quarter of the total AWD market. ce/gba

View full article